(NASDAQ: BNTX) Biontech Se's forecast annual revenue growth rate of -7.14% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.23%.
Biontech Se's revenue in 2026 is $3,300,235,294.On average, 25 Wall Street analysts forecast BNTX's revenue for 2026 to be $532,015,272,468, with the lowest BNTX revenue forecast at $474,902,221,116, and the highest BNTX revenue forecast at $647,201,258,388. On average, 23 Wall Street analysts forecast BNTX's revenue for 2027 to be $548,093,316,336, with the lowest BNTX revenue forecast at $339,318,716,856, and the highest BNTX revenue forecast at $754,228,236,972.
In 2028, BNTX is forecast to generate $649,600,966,428 in revenue, with the lowest revenue forecast at $323,240,672,988 and the highest revenue forecast at $845,657,113,296.